Highlights: · The dual antiplatelet therapy (DAPT), comprising aspirin and a P2Y12 inhibitor is recommended in patients with acute coronary syndrome (ACS) and undergoing percutaneous coronary intervention (PCI) with drug-eluting stents. Although this treatment strategy increases bleeding risk even in ACS patients having a high thrombotic risk.
1,2,3 · Instead of 6-12 months of DAPT, ticagrelor monotherapy after short-term DAPT can be effective alternative. It is associated with reduced bleeding risk and decreased all-cause mortality.4